Chemours Gelecekteki Büyüme
Future kriter kontrolleri 4/6
Chemours kazanç ve gelirin sırasıyla yıllık 136% ve 5.2% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 135.9% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 68.7% olacağı tahmin edilmektedir.
Anahtar bilgiler
136.0%
Kazanç büyüme oranı
135.94%
EPS büyüme oranı
| Chemicals kazanç büyümesi | 17.1% |
| Gelir büyüme oranı | 5.2% |
| Gelecekteki özkaynak getirisi | 68.73% |
| Analist kapsamı | Good |
| Son güncelleme | 11 May 2026 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Analiz Makalesi • May 08
The Chemours Company Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts
It's been a mediocre week for The Chemours Company ( NYSE:CC ) shareholders, with the stock dropping 17% to US$22.41 in...Seeking Alpha • May 04
Chemours: Thesis Materialization In 2026 (Rating Downgrade)
Summary Chemours Company has delivered a 120%+ RoR in under six months, driven by strong refrigerant segment growth, especially Opteon adoption. Despite recent outperformance, CC now trades above my fair value target ($30/share), prompting a shift to a 'HOLD/Neutral' rating and portfolio rotation. CC remains fundamentally sound but faces persistent risks: high leverage ($3.5B net debt), regulatory liabilities, and cyclical end-market exposure, especially in TiO2. Future upside hinges on continued refrigerant growth, cost reductions, and deleveraging; current valuation reflects excessive optimism relative to near-term fundamentals. Read the full article on Seeking Alpha
Analiz Güncellemesi • Apr 22
CC: Cooling Partnership And 2026 Outlook Will Support Further Earnings Upside
Analysts now cite slightly higher long term revenue growth, profit margin, and P/E assumptions as reasons for raising Chemours fair value estimate from $25.00 to $29.00 per share. What's in the News Chemours and 2CRSi entered a Joint Development Agreement following the qualification of Chemours' Opteon two phase immersion cooling fluid in current generation 2CRSi servers, aimed at advancing two phase cooling technologies for high density IT infrastructure and AI workloads (Key Developments).Analiz Güncellemesi • Apr 08
CC: Share Repurchases And 2026 Outlook Will Support Earnings Upside
Analysts have raised their Chemours price target from $21.00 to $25.00, citing updated assumptions around revenue growth, profit margins, and a lower future P/E multiple as key drivers of the change. What's in the News Chemours completed its share repurchase program announced on May 2, 2022, buying back 10,342,722 shares (6.76%) for a total of $309.28 million, with no additional shares repurchased between October 1, 2025 and December 31, 2025 (Key Developments).
Analiz Güncellemesi • Mar 24
CC: PFAS Litigation Will Drive Cautious Outlook Despite Cooling Technology Partnership
Analysts have maintained their $17.00 price target for Chemours, citing updated assumptions that include a 10.25% discount rate, 3.37% revenue growth, a 13.84% profit margin, and a future P/E of 3.87x, which they state continue to support the prior fair value view. What's in the News Chemours reported that between October 1, 2025 and December 31, 2025, it repurchased 0 shares for US$0 under its existing program and indicated that it has completed the buyback of 10,342,722 shares, or 6.76%, for US$309.28 million under the authorization announced on May 2, 2022 (Key Developments).Analiz Güncellemesi • Mar 09
CC: PFAS Legal Overhang And Cooling Partnership Will Shape Balanced Return Outlook
Analysts have raised their price target on Chemours from $13.00 to $17.00, citing updated assumptions around discount rate, revenue growth, profit margins, and future P/E that change their view of the company’s risk and earnings potential. What's in the News Chemours and 2CRSi entered a Joint Development Agreement after Chemours' Opteon two phase immersion cooling fluid was qualified in current generation 2CRSi servers, with a focus on advanced cooling for high density IT, AI, and next generation chips, and an emphasis on end user and environmental benefits.Analiz Güncellemesi • Feb 22
CC: Earnings Outlook And PFAS Legal Overhang Will Shape Future Upside
Analysts have revised their Chemours price target from $18.00 to $21.00, citing updated assumptions around discount rate, revenue growth, profit margin and future P/E that slightly adjust the risk and earnings profile they are using in their models. What's in the News Chemours issued new Full Year 2026 earnings guidance, with management indicating an expectation for Net Sales growth in the 3% to 5% range.Analiz Güncellemesi • Feb 08
CC: PFAS Class Action Risk Will Limit Future Shareholder Returns
Analysts have kept their Chemours fair value estimate steady at $13.00, with the latest price target grounded in unchanged fair value assumptions, along with updated views on discount rate, revenue growth, profit margin and future P/E levels. What's in the News On January 6, 2026, a Montana federal judge denied motions to dismiss a class action against DuPont/Chemours, 3M and several other gear and materials manufacturers related to alleged toxic PFAS chemicals in firefighter turnout gear.Analiz Makalesi • Feb 03
The Chemours Company (NYSE:CC) Shares Fly 27% But Investors Aren't Buying For Growth
The The Chemours Company ( NYSE:CC ) share price has done very well over the last month, posting an excellent gain of...
Analiz Güncellemesi • Jan 25
CC: Legal Overhang And Margin Reset Will Shape Balanced Outlook
Analysts have trimmed their price target on Chemours to about US$16 from roughly US$18, pointing to adjustments in profit margin expectations and valuation multiples, even though assumptions for revenue growth and future P/E have shifted. What's in the News A Montana federal judge denied motions to dismiss a class-action lawsuit involving PFAS in firefighter turnout gear, allowing claims against DuPont/Chemours and other manufacturers to move forward, including Racketeer Influenced Corrupt Organizations (RICO) claims that will remain active pending a related Ninth Circuit decision (Lawsuits & Legal Issues).Analiz Güncellemesi • Jan 11
CC: PFAS Lawsuit And Weaker Margins Will Restrain Future Shareholder Returns
Analysts have kept their Chemours fair value estimate steady at US$13.00. The latest price target update reflects adjusted assumptions around discount rate, revenue growth, profit margin and future P/E rather than a change in headline valuation.Analiz Güncellemesi • Dec 26
CC: Future Profitability Challenges Will Temper Benefits Of Completed Share Buybacks
Analysts have modestly raised their price target on Chemours to 13.00 dollars, reflecting slightly stronger revenue growth expectations and higher assumed future valuation multiples, while this is partially offset by a more cautious view on long term profitability and risk. What's in the News Completed a share repurchase program totaling 10,342,722 shares, representing 6.76% of outstanding shares, for $309.28 million under the buyback announced on May 2, 2022 (Key Developments).Analiz Güncellemesi • Dec 12
CC: Long-Term Margin Outlook Will Offset Near-Term Losses And Completed Buybacks
Analysts have raised their price target on Chemours from 11 dollars and 41 cents to 13 dollars, reflecting expectations for significantly stronger long term profit margins, despite slightly more conservative assumptions for revenue growth and valuation multiples. What's in the News Completed a share repurchase program totaling 10,342,722 shares, representing 6.76% of outstanding shares, for $309.28 million under the buyback announced on May 2, 2022 (Key Developments).Analiz Güncellemesi • Nov 01
CC: Global Supply Agreements And Buybacks Will Drive Undervalued Shares Higher
Analysts have adjusted their price target for Chemours. They are maintaining the fair value estimate at $17.78, but have slightly increased the discount rate and are projecting a modest decrease in both expected revenue growth and profit margin based on recent outlook factors.Analiz Güncellemesi • Oct 17
Low GWP Refrigerants And Advanced Materials Will Drive Future Success
Analysts have raised their price target for Chemours by $1.00, reflecting updated assumptions for modestly improved fair value and profit margin forecasts. What's in the News Chemours has entered into strategic agreements with SRF Limited to strengthen its global supply chain, enhance operational flexibility, and increase capacity for key materials such as fluoropolymers and fluoroelastomers (Key Developments).Analiz Güncellemesi • Oct 03
Low GWP Refrigerants And Advanced Materials Will Drive Future Success
Analysts have raised their price target for Chemours from $15.44 to $16.78, citing improved profit margins and slight increases in projected revenue growth as key factors for the update. What's in the News Chemours signed strategic agreements with SRF Limited to strengthen its global supply chain, increase operational flexibility, and secure fluoropolymer and fluoroelastomer capacity for multiple industries (Client Announcements).Analiz Güncellemesi • Sep 17
Low GWP Refrigerants And Advanced Materials Will Drive Future Success
The modest increase in Chemours’ Consensus Analyst Price Target reflects slightly higher forward P/E expectations, while the discount rate remains stable, resulting in a revised fair value of $15.44. What's in the News Chemours signed strategic agreements with SRF Limited to enhance global supply chain, increase operational flexibility, and access capacity for fluoropolymers and fluoroelastomers, with no upfront capital investment required.Analiz Makalesi • Sep 03
The Chemours Company (NYSE:CC) Held Back By Insufficient Growth Even After Shares Climb 33%
The Chemours Company ( NYSE:CC ) shares have continued their recent momentum with a 33% gain in the last month alone...Analiz Makalesi • Jul 26
Is It Time To Consider Buying The Chemours Company (NYSE:CC)?
The Chemours Company ( NYSE:CC ), is not the largest company out there, but it saw a significant share price rise of...Analiz Makalesi • Jul 04
The Chemours Company's (NYSE:CC) Price Is Right But Growth Is Lacking After Shares Rocket 30%
The Chemours Company ( NYSE:CC ) shares have had a really impressive month, gaining 30% after a shaky period...Analiz Makalesi • Jun 29
Chemours (NYSE:CC) Has No Shortage Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analiz Makalesi • May 14
We Like The Quality Of Chemours' (NYSE:CC) Earnings
Despite posting healthy earnings, The Chemours Company's ( NYSE:CC ) stock has been quite weak. Along with the solid...Analiz Makalesi • Apr 25
Is There An Opportunity With The Chemours Company's (NYSE:CC) 48% Undervaluation?
Key Insights The projected fair value for Chemours is US$23.71 based on 2 Stage Free Cash Flow to Equity Chemours is...Analiz Makalesi • Mar 19
What Is The Chemours Company's (NYSE:CC) Share Price Doing?
The Chemours Company ( NYSE:CC ), might not be a large cap stock, but it saw significant share price movement during...Analiz Makalesi • Mar 04
It's Down 27% But The Chemours Company (NYSE:CC) Could Be Riskier Than It Looks
To the annoyance of some shareholders, The Chemours Company ( NYSE:CC ) shares are down a considerable 27% in the last...Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 12/31/2028 | 6,712 | N/A | 379 | 724 | 7 |
| 12/31/2027 | 6,401 | 404 | 262 | 596 | 9 |
| 12/31/2026 | 6,049 | 182 | 190 | 517 | 9 |
| 3/31/2026 | 5,821 | -410 | 154 | 332 | N/A |
| 12/31/2025 | 5,808 | -386 | 51 | 264 | N/A |
| 9/30/2025 | 5,837 | -338 | -12 | 265 | N/A |
| 6/30/2025 | 5,850 | -430 | -54 | 258 | N/A |
| 3/31/2025 | 5,788 | 10 | -797 | -455 | N/A |
| 12/31/2024 | 5,782 | 69 | -993 | -633 | N/A |
| 9/30/2024 | 5,835 | 63 | -675 | -289 | N/A |
| 6/30/2024 | 5,814 | 106 | -693 | -297 | N/A |
| 3/31/2024 | 5,904 | -329 | 9 | 390 | N/A |
| 12/31/2023 | 6,078 | -253 | 186 | 556 | N/A |
| 9/30/2023 | 6,004 | -317 | -67 | 235 | N/A |
| 6/30/2023 | 6,294 | -87 | 117 | 405 | N/A |
| 3/31/2023 | 6,566 | 489 | 337 | 629 | N/A |
| 12/31/2022 | 6,831 | 578 | 448 | 755 | N/A |
| 9/30/2022 | 7,031 | 908 | 485 | 808 | N/A |
| 6/30/2022 | 6,933 | 881 | 500 | 818 | N/A |
| 3/31/2022 | 6,673 | 746 | 460 | 783 | N/A |
| 12/31/2021 | 6,345 | 608 | 537 | 814 | N/A |
| 9/30/2021 | 6,108 | 394 | 712 | 959 | N/A |
| 6/30/2021 | 5,662 | 256 | 720 | 947 | N/A |
| 3/31/2021 | 5,100 | 215 | 581 | 802 | N/A |
| 12/31/2020 | 4,969 | 219 | 540 | 807 | N/A |
| 9/30/2020 | 4,984 | -117 | 544 | 854 | N/A |
| 6/30/2020 | 5,140 | -117 | 452 | 843 | N/A |
| 3/31/2020 | 5,455 | -46 | 284 | 738 | N/A |
| 12/31/2019 | 5,526 | -52 | N/A | 650 | N/A |
| 9/30/2019 | 5,637 | 407 | N/A | 509 | N/A |
| 6/30/2019 | 5,876 | 606 | N/A | 563 | N/A |
| 3/31/2019 | 6,284 | 792 | N/A | 900 | N/A |
| 12/31/2018 | 6,638 | 995 | N/A | 1,140 | N/A |
| 9/30/2018 | 6,749 | 1,081 | N/A | 1,184 | N/A |
| 6/30/2018 | 6,705 | 1,013 | N/A | 954 | N/A |
| 3/31/2018 | 6,476 | 893 | N/A | 795 | N/A |
| 12/31/2017 | 6,183 | 746 | N/A | 640 | N/A |
| 9/30/2017 | 5,930 | 288 | N/A | 607 | N/A |
| 6/30/2017 | 5,744 | 285 | N/A | 693 | N/A |
| 3/31/2017 | 5,540 | 106 | N/A | 599 | N/A |
| 12/31/2016 | 5,400 | 7 | N/A | 594 | N/A |
| 9/30/2016 | 5,438 | 151 | N/A | 626 | N/A |
| 6/30/2016 | 5,526 | -82 | N/A | 541 | N/A |
| 3/31/2016 | 5,651 | -82 | N/A | 456 | N/A |
| 12/31/2015 | 5,717 | -90 | N/A | 182 | N/A |
| 9/30/2015 | 5,906 | 75 | N/A | 372 | N/A |
| 6/30/2015 | 6,052 | 211 | N/A | 501 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: CC önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 3.5% ) daha hızlı bir büyüme olarak değerlendiriliyor.
Kazançlar ve Piyasa: CC önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.
Yüksek Büyüme Kazançları: CC önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.
Gelir ve Pazar: CC şirketinin gelirinin (yıllık 5.2% ) US pazarından (yıllık 11.6% ) daha yavaş büyümesi öngörülüyor.
Yüksek Büyüme Geliri: CC şirketinin gelirinin (yıllık 5.2% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: CC 'nin Özsermaye Getirisi'nin 3 yıl içinde çok yüksek olması tahmin ediliyor ( 68.7 %).
Büyüyen şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/11 09:24 |
| Gün Sonu Hisse Fiyatı | 2026/05/08 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
The Chemours Company 19 Bu analistlerden 9, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| null null | Alembic Global Advisors |
| David Coleman | Argus Research Company |
| Michael Leithead | Barclays |